Key result
A review of cardiovascular disease in women highlights historical differences in investigation and treatment compared to men, underrepresentation in clinical trials, and the influence of risk factors.
This review highlights the historical underrepresentation of women in cardiovascular clinical trials and disparities in receiving guideline-directed medical therapy.
Supports inclusive trial design to address sex disparities in CV care; leaves open effects on outcomes.
Cardiovascular disease (CVD) is a significant health care problem in the United States today. Women comprise an increasing component of the population affected by this disease. Recent reports have suggested that women are not enrolled in adequate numbers in major clinical studies and, furthermore, are less likely to receive treatment as recommended by evidence-based medicine guidelines. Historical differences in the investigation and treatment of cardiovascular disease between women and men are discussed. Reasons for differences in study enrollment of women are proposed. Efforts by the Food and Drug Administration to improve data collection in women are outlined. The influence of major risk factors, including smoking, hyperlipidemia, and hypertension, on development and progression of CVD is addressed. Major trials of CVD and heart failure are examined. An assessment of progress toward a goal of gender treatment equality is made.
No takes yet. Share an insight, caveat, or question.
Mary H. Parker (2003) conducted a review in Cardiovascular disease. A review of cardiovascular disease in women highlights historical differences in investigation and treatment compared to men, underrepresentation in clinical trials, and the influence of risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: